Wedbush Starts Unum Therapeutics (UMRX) at Outperform

Wedbush initiates coverage on Unum Therapeutics (NASDAQ: UMRX) with a Outperform rating and a price target of $18.00.

Analyst David Nierengarten comments "UMRX shares are undervalued given the universal approach of their proprietary Antibody-Coupled T-Cell Receptor (ACTR) platform, an engineered cell construct with unique potential for treating many tumor types. With this approach, a patient’s T cells are engineered (with a CD16 domain) in order to bind the Fc region of monoclonal antibodies, which are directed to tumor antigens. This allows for targeting multiple tumors with a single autologous cell construct, but ACTR could also address tumor resistance and heterogeneity through antibody combinations. ACTR cell therapies can potentially be “tuned” in many settings using different antibody dosing."

For an analyst ratings summary and ratings history on Unum Therapeutics click here. For more ratings news on Unum Therapeutics click here.

Shares of Unum Therapeutics closed at $11.98 Friday.

You May Also Be Interested In

• Wolfe Research Starts AFLAC (AFL) at Underperform
• Rothschild Redburn Starts ResMed (RMD) at Neutral
• BHP (BHP:LN) (BHP) PT Raised to GBP28.25 at Barclays